Replies to post #129435 on Biotech Values

[ghmm]

The TID data seem better here then the BID, though I am not sure if they are stat sig. In the prior trial I don't believe TID showed a benefit.

The importance to pointing it out is relevance to XNPT's program. Regardless I think they have to get their compound to qD since the drug seems to be fairly well tolerated in these studies.

[DewDiligence]

[BG-12] Beats Copaxone with ease.

You evidently misread the press release. The study in question (‘CONFIRM’) does not have a direct statistical comparison of BG-12 to Copaxone; rather, in this study, BG-12 and Copaxone were compared to placebo and each was found to be statsig better.

Although the BG-12 arms were numerically better than the Copaxone arm on the primary endpoint of annualized relapse rate, is it wrong to say (as you did) that BG-12 “beats Copaxone with ease” insofar as there was no statistical test for such a comparison.

The trial description is at http://www.clinicaltrials.gov/ct2/show/NCT00451451 .

[masterlongevity]

doesn't look like it beat copaxone to me. They only show significance vs. PBO. If it beat copaxone, they would have stated that it was superior to copaxone